CXCL8 and neoplasm: The production of reduced concentrations of VEGF by htMSCs, leading to a less immunosuppressive tumor environment, in association with the recruitment of immune cells by IL-8 and MCP-1, after tumor cells establishment (first dose) and during tumor development (second dose), could explain the significant tumor growth control induced by the treatment protocol.